~~<i id='B1D7265B82'><strike id='B1D7265B82'><tt id='B1D7265B82'><pre id='B1D7265B82'></pre></tt></strike></i>~~

Home» comprehensive» focus

focus

author：entertainment 2025-08-23 12:10:41 Page View：37214

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Research misconduct: Proposed new rules face resistance
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

3 questions for the future of Biden's cancer moonshot

PresidentJoeBidenEliseAmendola/APWASHINGTON—ThelatestphaseofPresidentBiden’sCancerMoonshotinitiative

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

Stroke deaths set to near 10 million globally by 2050

AdobeThenumberofstrokedeathsworldwideissettoclimb50%tonearly10millionby2050,withmostcasesoccurringin